🚀 RECENT AI SUCCESS

Our AI successfully predicted the gap for $HLT and executed a BUY strategy, securing a +1.48% net profit.

UPGRADE TO SEE LIVE SIGNALS

$ALT

Altimmune Inc

United StatesUNITED STATES
FREE PREVIEW
📅 Next Earnings: Aug 11, 2026 🌙 Close🌐 Website🏛️ NASDAQ📁 Health Technology🏭 Biotechnology
AVG HISTORICAL GAP2.04%
MAX GAP RECORD7.75%
PREMIUM
AI ACCURACY RATE
92.4%
Unlock AI Insights 🔓

LAST 10 EARNINGS GAPS (%)

VOLATILITY & BIAS PROFILE

AVG VOLATILITY3.0%
Bullish Gaps
Bearish Gaps
Neutral

Intelligence Brief

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a… Read full dossier

CURRENT AI SIGNAL
BULLISH STRONG
🔓 REVEAL SIGNAL

AI INSIGHTS & REPORTS FOR ALT

AI REPORT Jul 23

Sector Rotation: Analyzing Where Institutional Money Flows

AnalysisMarkets are experiencing a significant shift in sector rotation, driven by macroeconomic factors and changing risk sentiment. This…
VIEW REPORT_
AI REPORT Jul 23

Daily Champions: Unveiling the Market’s Hidden Opportunities

Analysis Markets are in a state of flux, with sentiment shifting rapidly as global macroeconomic factors come into…
VIEW REPORT_
AI REPORT Jul 22

Navigating Market Uncertainty: A Proven Portfolio Strategy

Analysis Markets are grappling with unprecedented volatility, driven by geopolitical tensions, inflationary pressures, and shifting macroeconomic dynamics. In…
VIEW REPORT_
AI MARKET SCANNING